So how good is orthodox breast cancer treatment?

So how good is orthodox breast cancer treatment?

A breast cancer patient recently wrote to us at CANCERactive. She is 52 and has breast cancer, ER+ and Her-2+.

The programme being offered offered by her oncologist is:

Surgery plus radiotherapy, then

3 rounds FEC
3 rounds FEC-T
Tamoxifen then an Aromatase Inhibitor
Herceptin

Her oncologist provided the following data:

5-year survival

40 out of 100 women are alive at 5 years with no adjuvant therapy after surgery

An extra 13 out of 100 women treated are alive because of hormone therapy

An extra 30 out of 100 women treated are alive because of hormone therapy & chemotherapy

An extra 37 out of 100 women treated are alive because of hormone therapy, chemotherapy and Trastuzumab

Total 77 out of 100

10-year survival

12 out of 100 women are alive at 10 years with no adjuvant therapy after surgery

An extra 11 out of 100 women treated are alive because of hormone therapy

An extra 32 out of 100 women treated are alive because of hormone therapy & chemotherapy

An extra 37 out of 100 women treated are alive because of hormone therapy, chemotherapy and Trastuzumab

Total 49 out of 100

According to the Eurocare studies, breast cancer treatment is the best performing area of orthodox treatment.

2016 Research
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Our
Newsletter

Join Our Newsletter Signup today for free and be the first to get notified on new updates.